The U.S. Food and Drug Administration announced on September 28, 2026, that it approved Emcitate (tiratricol), the first FDA-approved MCT8 deficiency treatment. The approval covers peripheral thyrotoxicosis—excess thyroid hormone in the bloodstream that causes symptoms—in patients with this rare genetic condition, also known as Allan-Herndon-Dudley syndrome.
According to the FDA’s approval announcement, Emcitate reduced elevated blood thyroid hormone levels and improved cardiovascular and metabolic symptoms in clinical studies. The agency also identified common side effects and cautioned that Emcitate should not be used together with another thyroid medication.
What the MCT8 deficiency treatment approval covers
Emcitate is approved as tablets for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency. The FDA describes this excess of thyroid hormone in the blood as a cause of symptoms such as rapid heart rate, increased blood pressure, and adverse effects on metabolism.
The distinction between the underlying condition and the approved treatment target matters. MCT8 deficiency affects thyroid hormone transport into the brain, while this approval addresses the effects of excess hormone circulating in the bloodstream. The announcement reports improvements in blood hormone levels and related cardiovascular and metabolic symptoms; it does not describe Emcitate as a cure for the genetic disorder.
The FDA granted the approval to Egetis Therapeutics US Inc. Before this approval, patients with MCT8 deficiency had no FDA-approved treatment option, according to the agency.
Who may be affected?
MCT8 deficiency is a rare genetic disorder that primarily affects males. It is caused by a faulty gene that provides instructions for making the MCT8 transporter, a protein responsible for carrying thyroid hormone into the brain.
The FDA explains that when this transporter does not function properly, the brain receives too little thyroid hormone while excessive levels build up in the bloodstream. The condition therefore involves both insufficient hormone delivery to the brain and excess hormone in the blood.
Many patients experience substantial developmental and physical limitations. The agency lists inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties, and chronic stress on the heart and metabolism among the condition’s effects.
What the clinical studies found
The FDA evaluated Emcitate’s effectiveness using two clinical studies involving patients ranging from infants to adults. These included an international, multicenter, randomized, placebo-controlled trial and a longer-term open-label study.
Across both studies, patients treated with Emcitate had reductions in excess thyroid hormone levels in the bloodstream. The agency also reported improvements in cardiovascular and metabolic symptoms affected by thyroid hormone levels, including systolic blood pressure and heart rate.
According to the FDA, tiratricol can enter cells without relying on the MCT8 transporter. The agency said this allows the medicine to bypass the transporter problem and decrease elevated blood thyroid hormone levels.
Safety information and when to read the official notice
The FDA describes Emcitate as a once-daily liquid suspension taken by mouth or through a feeding tube for patients who have difficulty swallowing. This is the administration information reported in the announcement, not an individualized treatment plan.
The most common side effects reported were diarrhea, vomiting, rash, and excessive sweating. The agency’s specific safety instruction is that patients taking another thyroid medication should talk to their healthcare provider before starting Emcitate, because the two should not be used together.
Patients and caregivers seeking the agency’s wording on the approved use, study findings, administration options, or medication warning should consult the linked official announcement. In particular, anyone already taking another thyroid medication should note the FDA’s instruction to discuss it with their healthcare provider before starting Emcitate.
Frequently Asked Questions
What did the FDA approve Emcitate to treat?
Emcitate is approved to treat peripheral thyrotoxicosis, or symptomatic excess thyroid hormone in the blood, in patients with MCT8 deficiency.
What benefits did the FDA report?
The agency reported lower excess blood thyroid hormone levels and improvements in related cardiovascular and metabolic symptoms, including systolic blood pressure and heart rate.
What is the FDA’s warning about other thyroid medication?
Patients taking another thyroid medication should talk to their healthcare provider before starting Emcitate. The FDA says the medications should not be used together.
